These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935 [TBL] [Abstract][Full Text] [Related]
7. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Timms JF; Cramer R; Camuzeaux S; Tiss A; Smith C; Burford B; Nouretdinov I; Devetyarov D; Gentry-Maharaj A; Ford J; Luo Z; Gammerman A; Menon U; Jacobs I Clin Chem; 2010 Feb; 56(2):262-71. PubMed ID: 20093557 [TBL] [Abstract][Full Text] [Related]
8. [Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology]. Xiu L; Li N; Wang WP; Chen F; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Cui W; Wu LY Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1188-1195. PubMed ID: 34794222 [No Abstract] [Full Text] [Related]
9. SELDI-TOF MS profiling of plasma proteins in ovarian cancer. Wu SP; Lin YW; Lai HC; Chu TY; Kuo YL; Liu HS Taiwan J Obstet Gynecol; 2006 Mar; 45(1):26-32. PubMed ID: 17272204 [TBL] [Abstract][Full Text] [Related]
10. High-resolution serum proteomic features for ovarian cancer detection. Conrads TP; Fusaro VA; Ross S; Johann D; Rajapakse V; Hitt BA; Steinberg SM; Kohn EC; Fishman DA; Whitely G; Barrett JC; Liotta LA; Petricoin EF; Veenstra TD Endocr Relat Cancer; 2004 Jun; 11(2):163-78. PubMed ID: 15163296 [TBL] [Abstract][Full Text] [Related]
11. Serum peptide profiling: identifying novel cancer biomarkers for early disease detection. Martorella A; Robbins R Acta Biomed; 2007; 78 Suppl 1():123-8. PubMed ID: 17465330 [TBL] [Abstract][Full Text] [Related]
12. Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer. Lee JH; Kim YH; Kim KH; Cho JY; Woo SM; Yoo BC; Kim SC Cancer Res Treat; 2018 Jul; 50(3):883-893. PubMed ID: 28934848 [TBL] [Abstract][Full Text] [Related]
13. [Study for drug-resistance of epithelial ovarian cancer by serum protein profiling]. Zhang WY; Zhu LR; Zheng YH; Zhou L; Zhang JZ; Wu JH; Liao QP Zhonghua Yi Xue Za Zhi; 2009 May; 89(19):1326-9. PubMed ID: 19615186 [TBL] [Abstract][Full Text] [Related]
14. Derivatized mesoporous silica beads for MALDI-TOF MS profiling of human plasma and urine. Terracciano R; Pasqua L; Casadonte F; Frascà S; Preianò M; Falcone D; Savino R Bioconjug Chem; 2009 May; 20(5):913-23. PubMed ID: 19338374 [TBL] [Abstract][Full Text] [Related]
15. Identification of candidate biomarkers using the Experion™ automated electrophoresis system in serum samples from ovarian cancer patients. Kim JH; Kim YW; Kim IW; Park DC; Kim YW; Lee KH; Jang CK; Ahn WS Int J Oncol; 2013 Apr; 42(4):1257-62. PubMed ID: 23443953 [TBL] [Abstract][Full Text] [Related]
16. Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads. Wu S; Xu K; Chen G; Zhang J; Liu Z; Xie X Int J Clin Oncol; 2012 Apr; 17(2):89-95. PubMed ID: 21638024 [TBL] [Abstract][Full Text] [Related]
17. Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics. Shield-Artin KL; Bailey MJ; Oliva K; Liovic AK; Barker G; Dellios NL; Reisman S; Ayhan M; Rice GE Proteomics Clin Appl; 2012 Apr; 6(3-4):170-81. PubMed ID: 22532453 [TBL] [Abstract][Full Text] [Related]
18. Investigation of early and advanced stages in ovarian cancer using human plasma by differential scanning calorimetry and mass spectrometry. Kim NA; Jin JH; Kim KH; Lim DG; Cheong H; Kim YH; Ju W; Kim SC; Jeong SH Arch Pharm Res; 2016 May; 39(5):668-76. PubMed ID: 27002828 [TBL] [Abstract][Full Text] [Related]
19. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. Koomen JM; Li D; Xiao LC; Liu TC; Coombes KR; Abbruzzese J; Kobayashi R J Proteome Res; 2005; 4(3):972-81. PubMed ID: 15952745 [TBL] [Abstract][Full Text] [Related]
20. A new approach for the analysis of mass spectrometry data for biomarker discovery. Barbarini N; Magni P; Bellazzi R AMIA Annu Symp Proc; 2006; 2006():26-30. PubMed ID: 17238296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]